Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement
ConclusionsIT rituximab was well tolerated in PMS patients and had transient effects on CSF biomarkers but did not change LME.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research